These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 21060072)

  • 21. Clopidogrel in acute coronary syndrome: implications of recent study findings.
    Duerschmied D; Bode C; Moser M
    Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1215-29. PubMed ID: 20828343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    ; Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Eikelboom JW; Fox KA; Granger CB; Jolly S; Joyner CD; Rupprecht HJ; Widimsky P; Afzal R; Pogue J; Yusuf S
    N Engl J Med; 2010 Sep; 363(10):930-42. PubMed ID: 20818903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
    Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Cooper A; Cairns R; Cannon CP; Wallentin L
    Eur Heart J; 2011 Dec; 32(23):2945-53. PubMed ID: 21804104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
    James SK; Storey RF; Khurmi NS; Husted S; Keltai M; Mahaffey KW; Maya J; Morais J; Lopes RD; Nicolau JC; Pais P; Raev D; Lopez-Sendon JL; Stevens SR; Becker RC;
    Circulation; 2012 Jun; 125(23):2914-21. PubMed ID: 22572911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK;
    Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.
    Scirica BM; Cannon CP; Emanuelsson H; Michelson EL; Harrington RA; Husted S; James S; Katus H; Pais P; Raev D; Spinar J; Steg PG; Storey RF; Wallentin L;
    J Am Coll Cardiol; 2011 May; 57(19):1908-16. PubMed ID: 21545948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
    Husted S; Harrington RA; Cannon CP; Storey RF; Mitchell P; Emanuelsson H
    Int J Clin Pract; 2009 Apr; 63(4):667-70. PubMed ID: 19335707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
    Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
    J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
    Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
    Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Quilici J; Grosdidier C; Fourcade L; Gaborit B; Pankert M; Molines L; Morange PE; Bonnet JL; Alessi MC
    Am J Cardiol; 2011 Nov; 108(10):1411-6. PubMed ID: 21872198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.